COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status
Language English Country United States Media print-electronic
Document type Journal Article
- Keywords
- COBLL1, Chronic lymphocytic leukemia, IGHV mutational status, LPL, ZAP70, prognosis,
- MeSH
- Survival Analysis MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell diagnosis genetics mortality MeSH
- Adult MeSH
- Gene Expression MeSH
- Middle Aged MeSH
- Humans MeSH
- Lipoprotein Lipase genetics MeSH
- Mutation * MeSH
- Biomarkers, Tumor MeSH
- Prognosis MeSH
- Disease Progression MeSH
- ZAP-70 Protein-Tyrosine Kinase genetics MeSH
- Reproducibility of Results MeSH
- ROC Curve MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Immunoglobulin Heavy Chains genetics MeSH
- Transcription Factors genetics MeSH
- Immunoglobulin Variable Region genetics MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- COBLL1 protein, human MeSH Browser
- Lipoprotein Lipase MeSH
- LPL protein, human MeSH Browser
- Biomarkers, Tumor MeSH
- ZAP-70 Protein-Tyrosine Kinase MeSH
- Immunoglobulin Heavy Chains MeSH
- Transcription Factors MeSH
- Immunoglobulin Variable Region MeSH
- ZAP70 protein, human MeSH Browser
The clinical course of chronic lymphocytic leukemia (CLL) is highly variable. Patients with unmutated IGHV (U-CLL) usually progress rapidly, whereas patients with mutated IGHV (M-CLL) have a more indolent disease. The expression of several genes correlates closely with the IGHV mutational status and could be used to assess prognosis in CLL. We analyzed the prognostic relevance of COBLL1, LPL, and ZAP70 gene expression, which correlated with IGHV mutational status (p < 0.0001), in 117 CLL patients and established a prognostic parameter dividing the tested cohort according to the disease aggressiveness. Our prognostic parameter was validated on an independent cohort of 161 CLL patients and achieved a high accuracy (94%). Patients divided according to the prognostic parameter differ in overall survival and time to first treatment (p < 0.0001, HR = 2.300/5.970, 95% CI: 1.587-3.450/4.621-15.86). Our approach provides a reliable alternative method to prognosis assessment via IGHV mutational status analysis.
c GENERI BIOTECH s r o Hradec Kralove Czech Republic
f Institute of Experimental Biology Faculty of Science Masaryk University Brno Czech Republic
References provided by Crossref.org
